Intellia Therapeutics |

Intellia engages in the research and development of genome editing therapies for cancer, genetic diseases, viral infections and inflammatory disorders.

What section would you like to update?
  • Company Logo
  • Company Name & URL
  • Company Description
  • Founded Date
  • Company Status
  • HQ Address
  • Social Links
  • CEO Name & Picture
  • Competitor Set
  • Funding Events
  • Acquisition Events

If you'd like to make any changes to this portfolio we'd be happy to help. Please send info/sources to support@owler.com.


We'll be back up as soon as possible.

Visit owler.uservoice.com for FAQs

Intellia Therapeutics Revenue, Funding, Number of Employees, Competitors and Acquisitions

INTELLIA THERAPEUTICS CEO

John Leonard

President & CEO

John Leonard

Approval Rating: 90/100

WEIGH-IN

How would you rate John Leonard as a CEO?

negative
You
neutral
You
positive
You

Founded:

2014

Headquarters:

CambridgeMassachusetts

Status:

PublicNASDAQNTLA

Industry Sector:

Life Sciences

Biotechnology

Completeness:

100%

KEY STATS

Revenue

- -

What is Intellia Therapeutics's revenue?

<1M

Employees

- -

How many people work at Intellia Therapeutics?

Followers on Owler

- -

FOLLOW
UNFOLLOW

TOP COMPETITORS

Add a new competitor:

Thanks for your contribution!

Recalculating The Competitive Graph now...

ADD

Intellia Therapeutics was founded in 2014 and its headquarters is located in Cambridge, Massachusetts, USA. Intellia Therapeutics has $24.0M in revenue and 10 employees. Intellia Therapeutics' top competitors are Synthego, Spark Therapeutics and True North Therapeutics.

Intellia Therapeutics Competitive Set

COMPANYLEADERSHIPCEO SCORE

EMPLOYEES
(ESTIMATED IF PRIVATE)

TOTAL FUNDING

REVENUE
(ESTIMATED IF PRIVATE)

LIKELY OUTCOME
Intellia TherapeuticsIntellia Therapeutics ceo

John Leonard

President & CEO

90/100
1Synthego ceoSynthego

Paul Dabrowski

CEO

65/100
$49.7M$3M
2Spark Therapeutics ceoSpark Therapeutics

Jeffrey D Marrazzo

Co-Founder & CEO

89/100213$377.8M$21M
3True North Therapeutics ceoTrue North Therapeutics

Nancy Stagliano

Co-Founder & CEO

76/10010$142M$<1M
4Editas Medicine ceoEditas Medicine

Katrine S. Bosley

President & CEO

83/10089$257.4M$11M
5CRISPR Therapeutics ceoCRISPR Therapeutics

Samarth Kulkarni

CEO

95/10022$218M$11M
6eGenesis ceoeGenesis

Jodie Morrison

President & CEO

90/100
$40M$8.5M
7Toolgen ceoToolgen

Jongmoon Kim

CEO

60/100
$15M
84D Molecular Therapeutics ceo4D Molecular Therapeutics

David Kirn

Co-Founder & CEO

55/100
$21.6M$5M

Intellia Therapeutics Revenue History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

$

Community Estimate

UPDATE THIS

Intellia Therapeutics Employee History

company revenue img

Coming soon with Owler Pro!

If you'd like to learn more, please contact us at support@owler.com

Community Estimate

UPDATE THIS

Intellia Therapeutics Leadership

NAMETITLESOCIAL MEDIA
John Leonard
John Leonard

President & CEO

President & CEO

Intellia Therapeutics Funding History

Since Intellia Therapeutics was founded in 2014, it has participated in 3 rounds of funding. In total Intellia Therapeutics has raised $193.0M. Intellia Therapeutics' last funding round was on May 2016 for a total of $108.0M

ROUNDFUNDING DATE AMOUNTINVESTORS
IPOMay 2016$108M
Series BAug 2015$70MOrbiMed HealthCare Fund ManagementFidelity Management and Research CompanyJanus Capital GroupForesite CapitalSectoral Asset ManagementEcoR1 CapitalAtlas VentureNovartis
Series ANov 2014$15MAtlas VentureNovartis

Total: $

Intellia Therapeutics News

Intellia Therapeutics: Here's What Pushed Intellia Therapeutics Inc. Up 33.7% in JanuaryNeither the CRISPR/Cas9 start-up nor its gene-editing peers had much to say last month, but it only took a suggestion of positive signs from elsewhere to send them rocketing higher.The Motley Fool
Intellia Therapeutics: Intellia Therapeutics to Present at February Healthcare Investor ConferencesCAMBRIDGE, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present or host one-on-one meetings at the following upcoming healthcare conferences in February: Wednesday, February 14, 2018 Leerink Partners 7th Annual Healthcare Conference Who: Tom Barnes, Ph.D., [...]Stock Guru
Intellia Therapeutics: Uh-oh! CRISPR gene-editing stocks may be worthlessA new study suggests that CRISPR may not work in people.USA TODAY
This week, Intellia Therapeutics made the news 13 times, an unusually high amount for the Cambridge companyIntellia Therapeutics made the news 13 times in the past week, including articles in BioPortfolio, Stock Guru and 4-traders. This is about 13 times more than the usual press coverage the company receives. Its top competitor, Editas Medicine, was mentioned five times and close competitor CRISPR Therapeutics was never mentioned.
Intellia Therapeutics: Intellia Therapeutics Gears Up for Secondary Offering24/7 Wall St.
Intellia Therapeutics: Intellia Therapeutics to Present at November Healthcare Investor ConferencesCAMBRIDGE, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November:Tuesday, November 7, 2017Credit Suisse 26th Annual Healthcare ConferenceWho: Tom Barnes, Ph.D., Senior Vice President, Innovation SciencesLocation: Scottsdale, ArizonaPresentation Time: 9:45am MST (11:45am EST)Wednesday, November 15, 2017Jefferies London Healthcare ConferenceWho: John Leonard, M.D., Executive Vice President, R&DLocation: London, United KingdomPresentation Time: 8:40am GMT (2:40am EST)Thursday, November 30, 2017Barclays Gene Editing/Therapy SummitWho: Nessan Bermingham, Ph.D., Chief Executive Officer and FounderLocation: New York, New YorkPresentation Time: ...Full story available on Benzinga.comBenzinga
Intellia Therapeutics: BRIEF-Intellia Therapeutics prices public offering of 6.3 mln shares at $24 per share* Intellia Therapeutics announces pricing of public offering of common stockReuters
Intellia Therapeutics: Intellia Therapeutics to Present at October Healthcare Investor ConferencesIntellia Therapeutics to Present at October Healthcare Investor ConferencesCAMBRIDGE, Mass., Oct.PharmiWeb
Intellia Therapeutics: BRIEF-Intellia therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9* Intellia Therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9 in one-year animal studyReuters
Intellia Therapeutics: Intellia Therapeutics to Present at Upcoming September Investor Healthcare ConferencesCAMBRIDGE, Mass., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare conferences. The Company also has appointed Lindsey Trickett as Vice President of Investor Relations.Upcoming Conferences:Tuesday, September 12, 2017Rodman & Renshaw 19th Annual Global Investment Conference Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer and FounderLocation: New York, New YorkPresentation Time: 2:35 pm EDTTuesday, September 26, 2017Cantor Fitzgerald 3rd Annual Healthcare ConferenceWho: Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences & eXtelliaLocation: New York, New YorkPresentation Time: 9:10 am EDTWednesday, September 27, 2017Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Who: Nessan Bermingham, Ph.D., President, Chief Executive Officer ...Full story available on Benzinga.comBenzinga

SEE MORE

SEE LESS

Intellia Therapeutics Website History

Screengrabs of how the Intellia Therapeutics site has evloved. (Click to expand)

Intellia Therapeutics website history

Nov 2017

Intellia Therapeutics website history

Jun 2017

Intellia Therapeutics website history

Feb 2017

Intellia Therapeutics website history

Nov 2016

Intellia Therapeutics website history

Aug 2016

Intellia Therapeutics website history

May 2016

Intellia Therapeutics website history

Feb 2016

Intellia Therapeutics website history

Nov 2015

Intellia Therapeutics website history

Jul 2015

Intellia Therapeutics website history

Jul 2015

Intellia Therapeutics website history

Apr 2015

Intellia Therapeutics website history

Nov 2014

Owler has collected 12 screenshots of Intellia Therapeutics' website since Nov 2014. The latest Intellia Therapeutics website design screenshot was captured in Nov 2017.

Intellia Therapeutics Headquarters

undefined company logo

40 Erie St

Cambridge, Massachusetts 02139

857-285-6200

Driving Directions

google map

Intellia Therapeutics Summary Information

Intellia engages in the research and development of genome editing therapies for cancer, genetic diseases, viral infections and inflammatory disorders. Intellia Therapeutics was founded in 2014. Intellia Therapeutics' headquarters is located in Cambridge, Massachusetts, USA 02139. It has raised 193.0M in 3 rounds. The latest round was in May 2016. Some of Intellia Therapeutics' investors include OrbiMed HealthCare Fund Management, Fidelity Management and Research Company and Janus Capital Group. Intellia Therapeutics' President & CEO, John Leonard, currently has an approval rating of 90%. 100% of Owler community believes the stock will go Up. Intellia Therapeutics has 10 employees and reported 24.0M in revenue [trailing four quarters].

Intellia Therapeutics's President & CEO, John Leonard, currently has an approval rating of 90%. Intellia Therapeutics's primary competitors are  Synthego Spark Therapeutics True North Therapeutics.

Visit the Intellia Therapeutics website to learn more.